Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...

The Patent Trial and Appeal Board agreed with Pfizer and its German partner that Moderna's patents were invalid based on "prior art" that disclosed the inventions before Moderna patented them. The ...

Moderna reports larger-than-expected quarterly loss Revenue falls 66% but beats expectations FDA pauses norovirus vaccine trial after adverse event report Feb 14 (Reuters) - Moderna (MRNA.O ...

(Reuters) -Moderna ... COVID-19 vaccine in late 2023, including at contract drug manufacturer Lonza's facility in Switzerland, as part of an effort that reduced cost of sales by $3.2 billion ...

Amid the measles outbreak that the CDC says will 'expand rapidly,' an expert explains how to know if you're protected from ...

(Reuters) -Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a rare neurological ... The company reported a larger-than-expected ...

In an early clinical trial, an experimental norovirus vaccine given as a pill produced defensive responses exactly where it counts—in the saliva of older people most vulnerable to the explosive ...

Moderna has ... that a bivalent booster vaccine, if authorised, would create a new tool as we continue to respond to emerging variants," added Bancel. The phase 1/2 study involved 895 subjects ...

Analysts expect Moderna to report quarterly losses of $2.68 per share and revenue of $942.84 million. COVID-19 vaccine demand and sales will be on watch. Every week, our Whisper Index uncovers ...

while revenue fell to $966M from $2.81B but beat the $942.8M consensus Moderna’s norovirus vaccine trial is on FDA hold due to a Guillain-Barré syndrome case but expects no impact on efficacy ...